Single-dose pharmacokinetics and tolerability of oral delta-9-tetrahydrocannabinol in patients with amyotrophic lateral sclerosis

Drug Metabolism Letters

Volumn 6, Issue 2, 2012, Pages 102-108

  Joerger, Markus ^a   Wilkins, Justin ^b   Fagagnini, Stefania ^c   Baldinger, Reto ^a   Brenneisen, Rudolf ^d   Schneider, Ursula ^a   Goldman, Bea ^a   Weber, Markus ^a,c  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b Neuromuscular Diseases Unit ALS Clinic   (Belgium)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

Absorption; Amyotrophic lateral sclerosis; Pharmacokinetics; Tetrahydrocannabinol; Toxicity

Indexed keywords

DRONABINOL;

ADULT; AGED; AGGRESSIVENESS; AMYOTROPHIC LATERAL SCLEROSIS; ANXIETY; ARTICLE; BLOOD SAMPLING; CONFUSION; CONTROLLED STUDY; DISORIENTATION; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG TOLERABILITY; DYSPNEA; EUPHORIA; FEMALE; GASTROINTESTINAL DISEASE; HALLUCINATION; HEADACHE; HEART PALPITATION; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STANDING; THOUGHT DISORDER; VERTIGO; VISUAL ANALOG SCALE; WEAKNESS; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; CANNABINOID RECEPTOR AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PROSPECTIVE STUDIES; TETRAHYDROCANNABINOL;

EID: 84876727461     PISSN: 18723128     EISSN: None     Source Type: Journal    
DOI: 10.2174/187231212804096655     Document Type: Article

References (35)

1. Hall, W.; Degenhardt, L. Prevalence and correlates of cannabis use in developed and developing countries. Curr. Opin. Psychiatry, 2007, 20, 393-7.
2. Tramer, M.R.; Carroll, D.; Campbell, F.A.; Reynolds, D.J.; Moore, R.A.; McQuay, H.J. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. B.M.J., 2001, 323, 16-21.
3. Beal, J.E.; Olson, R.; Laubenstein, L.; Morales, J.O.; Bellman, P.; Yangco, B. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J. Pain Symptom. Manage., 1995, 10, 89-97.
4. Wissel, J.; Haydn, T.; Muller, J.; Brenneis, C.; Berger, T.; Poewe, W. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. J. Neurol., 2006, 253, 1337-41.
5. Ashton, J.C.; Milligan, E.D. Cannabinoids for the treatment of neuropathic pain: clinical evidence. Curr. Opin. Investig. Drugs, 2008, 9, 65-75.
6. Brenneisen, R. Pharmakokinetics. In: Cannabis and Cannabinoids; Grotenhermen F. R. E., Ed., Haworth Press: Binghamton, NY, U.S 2002, pp. 67-72.
7. Huestis, M.A. Human cannabinoid pharmacokinetics. Chem. Biodivers., 2007, 4, 1770-804.
8. Lemberger, L.; Crabtree, R.E.; Rowe, H.M. 11-hydroxy-9-tetrahydrocannabinol: pharmacology, disposition, and metabolism of a major metabolite of marihuana in man. Science, 1972, 177, 62-4.
9. Goodwin, R.S.; Gustafson, R.A.; Barnes, A.; Nebro, W.; Moolchan, E.T.; Huestis, M.A. Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids. Ther. Drug Monit., 2006, 28, 545-51.
10. Rothstein, J.D. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann. Neurol., 2009, 65 Suppl 1, S3-9.
11. Shoemaker, J.L.; Seely, K.A.; Reed, R.L.; Crow, J.P.; Prather, P.L. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J. Neurochem., 2007, 101, 87-98.
12. Puffenbarger, R.A.; Boothe, A.C.; Cabral, G.A. Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia, 2000, 29, 58-69.
13. Hampson, A.J.; Grimaldi, M.; Axelrod, J.; Wink, D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. U. S.A., 1998, 95, 8268-73.
14. Hagenbach, U.; Luz, S.; Ghafoor, N.; Berger, J.M.; Grotenhermen, F.; Brenneisen, R. The treatment of spasticity with Delta9-tetrahydrocannabinol in persons with spinal cord injury. Spinal Cord, 2007, 45, 551-62.
15. Gelinas, D.F.M.; Abood, M. Pilot study of safety and tolerability of delta 9-THC (Marinol) treatment for ALS. Amyotroph. Lateral Scler. Other Motor Neuron Disord., 2002, 3, 23-4.
16. Weber M.; Goldman B.; Truniger S. Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial. J. Neurol. Neurosurg. Psychiatry, 2010, 81, 1135-40.
17. Kaufmann, P.; Levy, G.; Montes, J.; Buchsbaum, R.; Barsdorf, A.I.; Battista, V. Excellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trial. Amyotroph. Lateral Scler., 2007, 8, 42-6.
18. Brooks B.R. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. J. Neurol. Sci., 1994, 124 Suppl, 96-107.
19. Naef, M.; Russmann, S.; Petersen-Felix, S.; Brenneisen, R. Development and pharmacokinetic characterization of pulmonal and intravenous delta-9-tetrahydrocannabinol (THC) in humans. J. Pharm. Sci., 2004, 93, 1176-84.
20. Brenneisen, R.; Meyer, P.; Chtioui, H.; Saugy, M.; Kamber, M. Plasma and urine profiles of Delta9-tetrahydrocannabinol and its metabolites 11-hydroxy-Delta9-tetrahydrocannabinol and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol after cannabis smoking by male volunteers to estimate recent consumption by athletes. Anal. Bioanal. Chem., 2010, 396, 2493-502.
21. Beal, S.L.; Sheiner, L.B. NONMEM Users Guides. San Francisco: NONMEM Project Group, University of California 1998.
22. Nadulski, T.; Pragst, F.; Weinberg, G.; Roser, P.; Schnelle, M.; Fronk, EM. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract. Ther. Drug Monit., 2005, 27, 799-810.
23. Killestein, J.; Hoogervorst, E.L.; Reif, M.; Kalkers, N.F.; Van Loenen, A.C.; Staats, PG. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology, 2002, 58, 1404-7.
24. Ungerleider, J.T.; Andyrsiak, T.; Fairbanks, L.; Ellison, G.W.; Myers, L.W. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv. Alcohol Subst. Abuse, 1987, 7, 39-50.
25. Naef, M.; Curatolo, M.; Petersen-Felix, S.; Arendt-Nielsen, L.; Zbinden, A.; Brenneisen, R. The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain, 2003, 105, 79-88.
26. Rossi, S.; De Chiara, V.; Musella, A.; Mataluni, G.; Sacchetti, L.; Siracusano, A. Caffeine drinking potentiates cannabinoid transmission in the striatum: interaction with stress effects. Neuropharmacology, 2009, 56, 590-7.
27. Ohlsson, A.; Lindgren, J.E.; Wahlen, A.; Agurell, S.; Hollister, L.E.; Gillespie, H.K. Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin. Pharmacol. Ther., 1980, 28, 409-16.
28. Kelly, P.; Jones, R.T. Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J. Anal. Toxicol., 1992, 16, 228-35.
29. Ohlsson, A.; Lindgren, J.E.; Wahlen, A.; Agurell, S.; Hollister, L.E.; Gillespie, H.K. Single dose kinetics of deuterium labelled delta 1-tetrahydrocannabinol in heavy and light cannabis users. Biomed. Mass Spectrom., 1982, 9, 6-10.
30. Grotenhermen, F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin. Pharmacokinet., 2003, 42, 327-60.
31. Wall, M.E.; Sadler, B.M.; Brine, D.; Taylor, H.; Perez-Reyes, M. Metabolism, disposition, and kinetics of delta-9-tetrahydro-cannabinol in men and women. Clin. Pharmacol. Ther., 1983, 34, 352-63.
32. Johansson, E.; Halldin, M.M.; Agurell, S.; Hollister, L.E.; Gillespie, H.K. Terminal elimination plasma half-life of delta 1-tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana. Eur. J. Clin. Pharmacol., 1989, 37, 273-7.
33. Strougo, A.; Zuurman, L.; Roy, C.; Pinquier, J.L.; van Gerven, J.M.; Cohen, A.F. Modelling of the concentration--effect relationship of THC on central nervous system parameters and heart rate--insight into its mechanisms of action and a tool for clinical research and development of cannabinoids. J. Psychopharmacol., 2008, 22, 717-26.
34. Smith-Kielland, A.; Skuterud, B.; Morland, J. Urinary excretion of 11-nor-9-carboxy-delta9-tetrahydrocannabinol and cannabinoids in frequent and infrequent drug users. J. Anal. Toxicol., 1999, 23, 323-32.
35. Fredericks, A.B.; Benowitz, N.L.; Savanapridi, C.Y. The cardiovascular and autonomic effects of repeated administration of delta-9-tetrahydrocannabinol to rhesus monkeys. J. Pharmacol. Exp. Ther., 1981, 216, 247-53.